|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 244.99 USD | +0.68% |
|
+1.71% | +18.38% |
| 02-19 | Health Care Up as FDA Fears Subside - Health Care Roundup | DJ |
| 02-18 | Sector Update: Health Care Stocks Decline Late Afternoon | MT |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 93.78B | 94.94B | 85.16B | 88.82B | 94.19B | |||||
Total Revenues | 93.78B | 94.94B | 85.16B | 88.82B | 94.19B | |||||
Cost of Goods Sold, Total | 29.76B | 30.99B | 26.24B | 27.04B | 30.06B | |||||
Gross Profit | 64.02B | 63.95B | 58.92B | 61.78B | 64.13B | |||||
Selling General & Admin Expenses, Total | 24.06B | 23.6B | 20.17B | 21.95B | 23.13B | |||||
R&D Expenses | 14.71B | 14.6B | 15.08B | 17.23B | 14.66B | |||||
Other Operating Expenses, Total | 38.77B | 38.21B | 35.25B | 39.18B | 37.8B | |||||
Operating Income | 25.25B | 25.75B | 23.66B | 22.6B | 26.33B | |||||
Interest Expense, Total | -183M | -276M | -772M | -755M | -971M | |||||
Interest And Investment Income | 53M | 490M | 1.26B | 1.33B | 1.06B | |||||
Net Interest Expenses | -130M | 214M | 489M | 577M | 85M | |||||
Currency Exchange Gains (Loss) | -236M | -328M | -366M | -214M | -254M | |||||
Other Non Operating Income (Expenses) | 991M | 1.83B | 1.66B | 1.48B | 851M | |||||
EBT, Excl. Unusual Items | 25.87B | 27.46B | 25.45B | 24.45B | 27.02B | |||||
Restructuring Charges | -452M | -521M | -798M | -269M | -512M | |||||
Merger & Related Restructuring Charges | -117M | -300M | -200M | -1.2B | -300M | |||||
Gain (Loss) On Sale Of Investments | 1.09B | -700M | -600M | -300M | 400M | |||||
Gain (Loss) On Sale Of Assets | 617M | 380M | 117M | 226M | 263M | |||||
Asset Writedown | -936M | -1.22B | -1.3B | -405M | -204M | |||||
In Process R&D Expenses | -900M | -783M | -313M | -211M | -81M | |||||
Legal Settlements | -2.3B | -900M | -6.9B | -5.5B | 6B | |||||
Other Unusual Items | -100M | -1.7B | -400M | -100M | - | |||||
EBT, Incl. Unusual Items | 22.78B | 21.72B | 15.06B | 16.69B | 32.58B | |||||
Income Tax Expense | 1.9B | 3.78B | 1.74B | 2.62B | 5.78B | |||||
Earnings From Continuing Operations | 20.88B | 17.94B | 13.33B | 14.07B | 26.8B | |||||
Earnings Of Discontinued Operations | - | - | 21.83B | - | - | |||||
Net Income to Company | 20.88B | 17.94B | 35.15B | 14.07B | 26.8B | |||||
Net Income - (IS) | 20.88B | 17.94B | 35.15B | 14.07B | 26.8B | |||||
Net Income to Common Incl Extra Items | 20.88B | 17.94B | 35.15B | 14.07B | 26.8B | |||||
Net Income to Common Excl. Extra Items | 20.88B | 17.94B | 13.33B | 14.07B | 26.8B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 7.93 | 6.83 | 13.88 | 5.84 | 11.13 | |||||
Basic EPS - Continuing Operations | 7.93 | 6.83 | 5.26 | 5.84 | 11.13 | |||||
Basic Weighted Average Shares Outstanding | 2.63B | 2.63B | 2.53B | 2.41B | 2.41B | |||||
Net EPS - Diluted | 7.81 | 6.73 | 13.72 | 5.79 | 11.03 | |||||
Diluted EPS - Continuing Operations | 7.81 | 6.73 | 5.2 | 5.79 | 11.03 | |||||
Diluted Weighted Average Shares Outstanding | 2.67B | 2.66B | 2.56B | 2.43B | 2.43B | |||||
Normalized Basic EPS | 6.14 | 6.54 | 6.28 | 6.35 | 7.01 | |||||
Normalized Diluted EPS | 6.05 | 6.44 | 6.21 | 6.29 | 6.95 | |||||
Dividend Per Share | 4.19 | 4.45 | 4.7 | 4.91 | 5.14 | |||||
Payout Ratio | 52.84 | 65.11 | 33.48 | 84.05 | 46.19 | |||||
American Depositary Receipts Ratio (ADR) | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | |||||
Supplemental Items | ||||||||||
EBITDA | 32.64B | 32.72B | 30.77B | 29.94B | 33.84B | |||||
EBITA | 29.95B | 30.05B | 28.16B | 27.1B | 30.93B | |||||
EBIT | 25.25B | 25.75B | 23.66B | 22.6B | 26.33B | |||||
EBITDAR | 32.94B | 33.02B | 30.97B | 30.14B | 34.04B | |||||
Effective Tax Rate - (Ratio) | 8.33 | 17.42 | 11.53 | 15.71 | 17.73 | |||||
Current Domestic Taxes | 1.52B | 2.38B | 2.7B | 2.2B | 1.16B | |||||
Current Foreign Taxes | 2.45B | 3.07B | 3.09B | 2.6B | 3.08B | |||||
Total Current Taxes | 3.98B | 5.45B | 5.8B | 4.8B | 4.24B | |||||
Deferred Domestic Taxes | 583M | -2.08B | -3.44B | -2.54B | 2.01B | |||||
Deferred Foreign Taxes | -2.66B | 418M | -619M | 356M | -470M | |||||
Total Deferred Taxes | -2.08B | -1.66B | -4.06B | -2.18B | 1.54B | |||||
Normalized Net Income | 16.17B | 17.17B | 15.91B | 15.28B | 16.88B | |||||
Interest Capitalized | 49M | 49M | 70M | 79M | 114M | |||||
Non-Cash Pension Expense | -798M | -1.37B | -1.57B | -1.17B | -814M | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | 2.7B | 2.1B | 500M | 600M | 1.6B | |||||
Selling and Marketing Expenses | 2.7B | 2.1B | 500M | 600M | 1.6B | |||||
Research And Development Expense From Footnotes | 15.61B | 15.39B | 15.4B | 17.44B | 14.75B | |||||
Net Rental Expense, Total | 300M | 300M | 200M | 200M | 200M | |||||
Imputed Operating Lease Interest Expense | 15.66M | 20.6M | 37.86M | 39.09M | 39.83M | |||||
Imputed Operating Lease Depreciation | 284M | 279M | 162M | 161M | 160M | |||||
Stock-Based Comp., Other (Total) | 1.14B | 1.14B | 1.16B | 1.18B | 1.35B | |||||
Total Stock-Based Compensation | 1.14B | 1.14B | 1.16B | 1.18B | 1.35B |
- Stock Market
- Equities
- JNJ Stock
- Financials Johnson & Johnson
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















